Related Experiment Video
Updated: Jul 19, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Group B Streptococcus: global incidence and vaccine development
Atul Kumar Johri1, Lawrence C Paoletti, Philippe Glaser
1School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India. akjohri14@yahoo.com
Abstract:
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
Related Concept Videos
Streptococcal Pharyngitis
Microorganisms in Medicine and Therapeutics
Bacterial Meningitis I: Introduction
Smallpox
Clinical Significance of Antibiotic Resistance
Vaccinations

